TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07154706: Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

Sponsor: Nuvation Bio Inc. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 180 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$5,051,508

Rescue Site Savings

+$3,345,804

Unlock Full NCT07154706 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07154706 Rescue Dossier →